MedTrace Logo

Topical Omega-3 Fatty Acids (REMOGEN® OMEGA) in the Treatment of Dry Eye

NCT02908282 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 81

Last updated 2018-08-15

No results posted yet for this study

Summary

The primary objective of this study is to evaluate the efficacy of REMOGEN® OMEGA in reducing Dry Eye Syndrome (DES) symptoms.

Conditions

  • Dry Eye Syndromes

Interventions

DEVICE

REMOGEN OMEGA

Lubricant eye drops: preservative-free, hypotonic microemulsion of polyunsaturated fatty acids and hydrating polymers provided in single-dose containers of 0.25 ml.

DEVICE

Povidone

Artificial tears: preservative-free eye drops containing 2% povidone.

Sponsors & Collaborators

  • TRB Chemedica AG

    lead INDUSTRY

Principal Investigators

  • Thomas Kaercher, Dr. · Praxis Dr. Thomas Kaercher

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
SINGLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
81 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2016-10-31
Primary Completion
2018-07-31
Completion
2018-07-31

Countries

  • Germany

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02908282 on ClinicalTrials.gov